|
|
|
题名
|
作者
|
年代
|
出处
|
被引量
|
| 1 | Liquid biopsy in patients with hepatocellular carcinoma: Circulating tumor cells and cell-free nucleic acids显示文摘Hepatocellular carcinoma(HCC), with its high incidence and mortality rate, is one of the most common malignant tumors. Despite recent development of a diagnostic and treatment method, the prognosis of HCC remains poor. Therefore, to provide optimal treatment for each patient with HCC, more precise and effective biomarkers are urgently needed which could facilitate a more detailed individualized decision-making during HCC treatment, including the following; risk assessment, early cancer detection, prediction of treatment or prognostic outcome. In the blood of cancer patients, accumulating evidence about circulating tumor cells and cell-free nucleic acids has suggested their potent clinical utilities as novel biomarker. This concept, so-called 'liquid biopsy' is widely known as an alternative approach to cancer tissue biopsy. This method might facilitate a more sensitive diagnosis and better decision-making by obtaining genetic and epigenetic aberrations that are closely associated with cancer initiation and progression. In this article, we review recent developments based on the available literature on both circulating tumor cells and cell-free nucleic acids in cancer patients, especially focusing on Hepatocellular carcinoma. | wataru okajima shuhei komatsu daisuke ichikawa mahito miyamae takuma ohashi taisuke imamura jun kiuchi keiji nishibeppu tomohiro arita hirotaka konishi atsushi shiozaki ryo morimura hisashi ikoma kazuma okamoto eigo otsuji | 2017 | World Journal of Gastroenterology2017，23，31： | 22 |
| 2 | Efficacy of an orally active small-molecule inhibitor of RANKL in bone metastasis显示文摘Bone is one of the preferred sites for the metastasis of malignant tumours,such as breast cancer,lung cancer and malignant melanoma.Tumour cells colonizing bone have the capacity to induce the expression of receptor activator of nuclear factor-κB ligand(RANKL),which promotes osteoclast differentiation and activation.Tumour-induced osteoclastic bone resorption leads to a vicious cycle between tumours and bone cells that fuels osteolytic tumour growth,causing bone pain and hypercalcaemia.Furthermore,RANKL contributes to bone metastasis by acting as a chemoattractant to bone for tumour cells that express its receptor,RANK.Thus inhibition of the RANKL–RANK pathway is a promising treatment for bone metastasis,and a human monoclonal anti-RANKL antibody,denosumab,has been used in the clinic.However,orally available drugs targeting RANKL must be developed to increase the therapeutic benefits to patients.Here we report the efficacy of the small-molecule RANKL inhibitor AS2676293 in treating bone metastasis using mouse models.Oral administration of AS2676293 markedly inhibited bone metastasis of human breast cancer cells MDA-MB-231-5a-D-Luc2 as well as tumour-induced osteolysis.AS2676293 suppressed RANKLmediated tumour migration in the transwell assay and inhibited bone metastasis of the murine cell line B16F10,which is known not to trigger osteoclast activation.Based on the results from this study,RANKL inhibition with a small-molecule compound constitutes a promising therapeutic strategy for treating bone metastasis by inhibiting both osteoclastic bone resorption and tumour migration to bone. | Yuta Nakai Kazuo Okamoto Asuka Terashima Shogo Ehata Jun Nishida Takeshi Imamura Takashi Ono Hiroshi Takayanagi | 2019 | Bone Research2019，7，1： | 8 |
| 3 | Cancer-derived VEGF plays no role in malignant ascites formation in the mouse显示文摘AIM: Vascular endothelial growth factor (VEGF) is a potent mediator of peritoneal fluid accumulation following tumor progression. This study investigated the role of VEGF secreted by cancerous cells in the formation of malignant ascites.METHODS: VEGF expression was eliminated byknockdown in the pancreas cancer cell-line PancO2 using vector-based short-hairpin type RNA interference (RNAi).Malignant ascites formation in the mouse was analyzed by intraperitoneal injection of PancO2 cells expressing VEGF or with expression knockdown.RESULTS: The VEGF knockdown PancO2 cell was successfully established. Knockdown of VEGF did not affect cancer cell proliferation in vitro or in vivo. The volume of ascites following peritoneal expansion of the tumor in VEGF knockdown cells and control cells did not differ statistically in this in vivo study. Moreover, the VEGF concentration in the ascites did not differ statistically.CONCLUSION: Malignant ascites formation might be mediated by VEGF production in noncancerous tissues,such as stromal compartments. An anti-VEGF strategy against malignant ascites could be applied to various tumors regardless of whether they secrete VEGF. | Bayasi Guleng Keisuke Tateishi Fumihiko Kanai Amarsanaa Jazag Miki Ohta Yoshinari Asaoka Hideaki Ijichi Yasuo Tanaka Jun Imamura Tsuneo Ikenoue Yasushi Fukushima Keita-Morikane Makoto Miyagishi Kazunari Taira Takao Kawabe Masao Omata | 2005 | World Journal of Gastroenterology2005，11，35： | 2 |
| 4 | Prospective risk assessment for hepatocellular carcinoma development in patients with chronic hepatitis C by transient elastography显示文摘 | Ryota Masuzaki Ryosuke Tateishi Haruhiko Yoshida Eriko Goto Takahisa Sato Takamasa Ohki Jun Imamura Tadashi Goto Fumihiko Kanai Naoya Kato Hitoshi Ikeda Shuichiro Shiina Takao Kawabe Masao Omata | 2009 | Hepatology2009，，： | 2 |
| 5 | Treatment strategy for hepatocellular carcinoma: expanding the indications for radiofrequency ablation显示文摘 | Ryosuke Tateishi Shuichiro Shiina Takamasa Ohki Takahisa Sato Ryota Masuzaki Jun Imamura Eriko Goto Tadashi Goto Hideo Yoshida Shuntaro Obi Shinpei Sato Fumihiko Kanai Haruhiko Yoshida Masao Omata | 2009 | Journal of Gastroenterology2009，，19： | 1 |
| 6 | Progression of a Sessile Serrated Adenoma to an Early Invasive Cancer Within 8?Months显示文摘 | Yasuhiro Oono Kuangi Fu Hisashi Nakamura Yosuke Iriguchi Akihiko Yamamura Yasuhiro Tomino Johji Oda Masaru Mizutani Satoshi Takayanagi Daisuke Kishi Tomoaki Shinohara Kozo Yamada Jun Matumoto Kazuhiro Imamura | 2009 | Digestive Diseases and Sciences2009，，4： | 1 |
| 7 | Ultrasound surveillance for early detection of hepatocellular carcinoma among patients with chronic hepatitis C显示文摘 | Takahisa Sato Ryosuke Tateishi Haruhiko Yoshida Takamasa Ohki Ryota Masuzaki Jun Imamura Tadashi Goto Fumihiko Kanai Shuntaro Obi Naoya Kato Shuichiro Shiina Takao Kawabe Masao Omata | 2009 | Hepatology International2009，，4： | 1 |
| 8 | Ultrasound surveillance for early detection of hepatocellular carcinoma among patients with chronic hepatitis C显示文摘 | Takahisa Sato Ryosuke Tateishi Haruhiko Yoshida Takamasa Ohki Ryota Masuzaki Jun Imamura Tadashi Goto Fumihiko Kanai Shuntaro Obi Naoya Kato Shuichiro Shiina Takao Kawabe Masao Omata | 2009 | Hepatology International2009，，4： | 1 |
| 9 | Clinicopathological characteristics of duodenal microgastrinomas显示文摘 | Masayuki Imamura M.D. Masahiro Kanda M.D. Kiyoyuki Takahashi M.D. Yutaka Shimada M.D. Tokiharu Miyahara M.D. Takashi Wagata M.D. Mitsuaki Hashimoto M.D. Takayoshi Tobe M.D. Jun Soga M.D | 1992 | World Journal of Surgery1992，，4： | 1 |
| 10 | Inhibition of Cyclic Adenosine Monophosphate (cAMP)-response Element-binding Protein (CREB)-binding Protein (CBP)/β-Catenin Reduces Liver Fibrosis in Mice显示文摘 | Yosuke Osawa Keisuke Oboki Jun Imamura Ekumi Kojika Yukiko Hayashi Tsunekazu Hishima Toshiji Saibara Futoshi Shibasaki Michinori Kohara Kiminori Kimura | 2015 | EBioMedicine2015，，11： | 1 |
| 11 | Adenocarcinoid of the Appendix: Report of Two Cases显示文摘 | Masaki Aizawa Osamu Watanabe Yoshihiko Naritaka Takao Katsube Hiroshi Imamura Jun Kinoshita Takeshi Shimakawa Satoshi Kobayashi Shinichi Asaka Shunsuke Haga Kenji Ogawa Motohiko Aiba Tetsuro Kajiwara | 2003 | Surgery Today2003，，5： | 1 |
| 12 | Regulation of RANKL‐induced osteoclastogenesis by TGF‐β through molecular interaction between Smad3 and Traf6显示文摘 | Tetsuro Yasui Yuho Kadono Masaki Nakamura Yasushi Oshima Takumi Matsumoto Hironari Masuda Jun Hirose Yasunori Omata Hisataka Yasuda Takeshi Imamura Kozo Nakamura Sakae Tanaka | 2011 | J Bone Miner Res2011，，7： | 1 |
| 13 | Temporary inferior vena cava filter for deep vein thrombosis and acute pulmonary thromboembolism: effectiveness and indication显示文摘 | Ryuichi Kai Hiroshi Imamura Setuo Kumazaki Yuichi Kamiyoshi Megumi Koshikawa Takeshi Hanaoka Kaoru Kogashi Jun Koyama Hiroshi Tsutsui Yoshikazu Yazaki Osamu Kinoshita Uichi Ikeda | 2006 | Heart and Vessels2006，，4： | 1 |
| 14 | Self-assembly of the ionic peptide EAK16: The effect of charge distributions on self-assembly显示文摘 | Jun S Hong Y Imamura H | 2004 | Biophysical J2004，87，： | 1 |
| 15 | Genetic analysis of non-insulin-dependent diabetes mellitus in KK and KK-Ay mice显示文摘 | Jun - ichi Suto Saori Matsuura Kenkichi Imamura | 1998 | European Journal of Endocrinology1998，139，： | 1 |
| 16 | Sisters with clinically mild encephalopathy with a reversible splenial lesion (MERS)-like features; Familial MERS?显示文摘 | Takuji Imamura Jun-ichi Takanashi Jun Yasugi Hitoshi Terada Akira Nishimura | 2009 | Journal of the Neurological Sciences2009，，1： | 1 |
| 17 | The New Plating Process on Plastics显示文摘This process does not use general electroless plating solution containing formaldehyde(carcinogen) and phosphate(the object of waste water regulation). Furthermore, we succeeded in developing a new electroless copper plating solution which is usable semi-permanently by using the special reducing agent. The electroless deposition forms a very thin conductive film on substrate. Therefore, it can prevent some appearance defects (e.g. pits, pin-holes, laminations and inclusions) that occur in the conventional ones. In addition, it is possible to eliminate electroplating of copper from the process by applying the exclusive nickel solution in electroplating. Therefore, the obtained metal parts can be recycled as high quality stainless steel. Given this copper electroplating-free process, 25 u m-thick nickel deposition at the stage of electroplating, at least, enables the metal layers to show properties as versatile as those of the conventional(its total thickness is 25 n m in the comparative conventional process). | Makoto Imamura Jun Okada Kazuya Satoh | 2004 | 材料热处理学报2004，25，05B： | 0 |
| 18 | Circulating microRNAs as a liquid biopsy: a next generation clinical biomarker for diagnosis of gastric cancer显示文摘Accumulating evidence has suggested the potential clinical utility of novel body fluid biomarkers,or“liquid biopsy”,using circulating tumor cells and cell-free nucleic acids from cancer patients.Noninvasive and reproducible,liquid biopsy could provide the basis for individualized therapeutic strategies by identifying genetic and epigenetic aberrations that are closely associated with cancer initiation and progression.MicroRNAs(miRNAs)are short noncoding RNAs that post-transcriptionally regulate gene expression.They also play important roles in various physiological and developmental processes as oncogenic or tumor-suppressive regulators.Specific miRNA expression signatures have been identified in a number of human cancers.Circulating miRNAs have been detected in plasma and serum,and this in blood has attracted the attention of researchers for their potential as noninvasive biomarkers.Circulating miRNAs have emerged as tumor-associated biomarkers that reflect not only the existence of cancer,but also the dynamics,malignant potential,and drug resistance of tumors.Herein,we review the recent biological and clinical research on the circulating miRNAs of gastric cancer and discuss future perspectives for their clinical applications as a liquid biopsy. | Shuhei Komatsu Jun Kiuchi Taisuke Imamura Daisuke Ichikawa Eigo Otsuji | 2018 | Journal of Cancer Metastasis and Treatment2018，4，1： | 0 |
| 19 | Stereotactic body radiation therapy for primary liver tumors with adverse factors显示文摘Aim:To test the efficacy and safety of liver stereotactic body radiation therapy(SBRT)in patients who harbor adverse factors.Methods:We retrospectively evaluated the outcomes of liver SBRT in a single cancer center.We invented criteria consisting of two physical factors and two tumor factors to measure the treatment difficulty in each case.The clinical outcomes and toxicity were evaluated by stratification of the harboring factors.Results:A total of 24(23 hepatocellular carcinoma and 1 intrahepatic cholangiocarcinoma)patients were eligible for this study,with a median follow-up duration of 18 months.Of all eligible patients,21 patients(88%)had one or more factors.The local control,progression-free survival,and overall survival rates for all patients at 2 years were 89%,42%,and 76%respectively.In the patients with physical and tumor adverse factors,local control/progression-free survival/overall survival rates at 2 years were 100%/42%/69%and 80%/23%/78%,respectively.The subgroup of 11 patients with 2 or more factors showed comparable local control rate at 2 years to the subgroup of 13 patients with 0 to 1 factors(100%vs.86%,P=0.59).One patient(4.2%)experienced a decline in the Child-Pugh score by 2 points at 3 months after the treatment.Grade 2 to 3 gastrointestinal toxicity was observed in three patients.Conclusion:SBRT showed a high local control rate with acceptable toxicity for the group of liver cancer patients harboring both physical and tumor adverse factors as long as conducted following patient selection and dose constraints that were used in this study. | Takuya Shimizuguchi Jun Imamura Simpei Hashimoto Katsuyuki Karasawa | 2020 | Hepatoma Research2020，6，10： | 0 |
您所在的机构暂未开通此部分的功能，请联系管理员